Screener
Tyra Biosciences, Inc. TYRA Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Tyra Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Tyra Biosciences, Inc.’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 8:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-220645
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | $33,470 | $24,964 |
| General and administrative | 8,528 | 6,886 |
| Total operating expenses | 41,998 | 31,850 |
| Loss from operations | (41,998) | (31,850) |
| Other income: | ||
| Interest and other income, net | 2,693 | 3,703 |
| Total other income | 2,693 | 3,703 |
| Net loss | (39,305) | (28,147) |
Item 1. Condensed Financial Statements
FAQ
- What is Tyra Biosciences, Inc.'s operating income?
- Tyra Biosciences, Inc. (TYRA) reported operating income of -$42M in Q1 2026.
- How has Tyra Biosciences, Inc.'s operating income changed year-over-year?
- Tyra Biosciences, Inc.'s operating income decreased by 31.9% year-over-year, from -$31.85M to -$42M.
- What is the long-term trend for Tyra Biosciences, Inc.'s operating income?
- Over 4 years (2021 to 2025), Tyra Biosciences, Inc.'s operating income has grown at a 49.9% compound annual growth rate (CAGR), from -$26.29M to -$132.76M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Tyra Biosciences, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude